AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 291 min read$BIVI

Palumbo Joseph M purchased $10K of BIVI

Palumbo Joseph M (Chief Medical Officer) purchased 4,843 shares of BIOVIE INC. (BIVI) at $2.16 on 2026-08-28.

Original reporting
SEC EDGAR · Palumbo Joseph M
Published Aug 29, 2026, 1:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 29, 2026, 1:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BIVI
Neutral
high confidence
Mentioned
$BIVI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BIVINeutralLow
01

Why it matters

The purchase is modest and unlikely to move the stock, but it confirms insider alignment with shareholders.

02

Market read

Routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming clinical data or partnership not disclosed in filing.

Relevance 4/10Novelty 3/10Timing: post-market 2026-08-28

Background

Form 4 filings disclose insider transactions; investors monitor for signals of confidence.

Company-level read

Ticker impact

$BIVINeutralHigh confidence
Context

Chief Medical Officer purchased 4,843 shares at $2.16 each, total $10.5K, filing a Form 4 on 2026-08-28.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

Purchase size is trivial relative to market cap; likely no immediate trading signal.

Market effects

Sector

No broader sector impact; biotech insider activity is routine.

Regional

None

Global

None

Counterpoint

What could challenge this read

Even small insider purchases can precede larger moves if insider has material knowledge.

Key entities

  • Officer
    Palumbo Joseph M

    Chief Medical Officer of BIOVIE INC.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BIVI insider trading history →

Related articles

OCT 26
$SPCXHighAI 8/10

MARKETS LIVE: Wall Street in the green as investors weigh Anthropic IPO filing

SpaceX committed to a $40B lease for Nvidia chips. Xencor shares rose 20% on positive drug trial results. Surgery Partners surged 46% after a $5.7B acquisition deal. Tesla gained 6% following a Barclays upgrade. Verizon raised 2026 guidance after strong customer additions. Anthropic filed for IPO, with concerns raised about its valuation and spending. FTSE 100 gained 0.7%. Big Tech earnings and Fed decision are key focuses this week.

proactiveinvestors.com3 min
OCT 24
$BIVIMedAI 8/10

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

New to The Street Show #777 features executives from Stewards Investment Capital, BioVie (NASDAQ:BIVI), FreeCast (NASDAQ:CAST), and American Fusion (OTCQB:AMFN). BioVie reports positive long COVID and Parkinson's trial results. FreeCast discusses its media monetization technology. American Fusion presents its fusion power technology. The show airs on Bloomberg Television and YouTube.

finanznachrichten.de2 min
OCT 20
$BIVIMedAI 8/10

BioVie reports positive Phase 2 Parkinson’s data for bezisterim

BioVie Inc. reported that its experimental Parkinson's drug, bezisterim, improved motor and non-motor symptoms in early-stage patients with higher inflammation, according to Phase 2 SUNRISE-PD trial results. In the subgroup of 28 patients, those treated with bezisterim showed improvement, while placebo patients worsened slightly. Across all 57 patients, 25% on bezisterim saw meaningful improvement versus 4% on placebo.

finance.yahoo.com2 min
OCT 20
$BIVIMedAI 8/10

BioVie reports positive bezisterim trial results in Parkinson’s

BioVie Inc. (BIVI) reported Phase 2 trial results for bezisterim in early-stage Parkinson’s patients. In a subgroup with high inflammation, bezisterim improved motor and non-motor scores versus placebo. Overall, bezisterim patients were 6.25x more likely to show meaningful improvement. Adverse events were lower in the treatment group. The trial enrolled untreated patients using a hybrid design. BioVie focuses on neurological and liver disease therapies.

investing.com2 min